BioSpace Collaborative

Academic/Biomedical Research
News & Jobs
Biotechnology and Pharmaceutical Channel Medical Device and Diagnostics Channel Clinical Research Channel BioSpace Collaborative    Job Seekers:  Register | Login          Employers:  Register | Login  

NEWSLETTERS
Free Newsletters
Archive
My Subscriptions

NEWS
News by Subject
News by Disease
News by Date
PLoS
Search News
Post Your News
JoVE

CAREER NETWORK
Job Seeker Login
Most Recent Jobs
Search Jobs
Post Resume
Career Fairs
Career Resources
For Employers

HOTBEDS
Regional News
US & Canada
  Biotech Bay
  Biotech Beach
  Genetown
  Pharm Country
  BioCapital
  BioMidwest
  Bio NC
  BioForest
  Southern Pharm
  BioCanada East
  US Device
Europe
Asia

DIVERSITY

PROFILES
Company Profiles

INTELLIGENCE
Research Store

INDUSTRY EVENTS
Research Events
Post an Event
RESOURCES
Real Estate
Business Opportunities

 News | News By Subject | News by Disease News By Date | Search News
Get Our Industry eNewsletter FREE email:    
   

Nephron Pharmaceuticals Announces Asthmanefrin™, an Alternative to Primatene® Mist


8/21/2012 12:18:02 PM

ORLANDO, Fla., Aug. 21, 2012 /PRNewswire/ -- Nephron Pharmaceuticals Corporation (Nephron) is proud to announce Asthmanefrin, a fast acting, safe and effective over-the-counter (OTC) alternative to the discontinued Primatene® Mist chlorofluorocarbon (CFC) inhaler.

Asthmanefrin will provide relief for millions of former Primatene® Mist users. The Primatene® Mist CFC inhaler was removed from the market by the Food and Drug Administration (FDA) and the Environmental Protection Agency (EPA) on Dec. 31, 2011. The inhaler was discontinued because of its CFC propellant. Asthmanefrin does not contain CFCs or preservatives. The active ingredient in Asthmanefrin, Racepinephrine, has been safely used by hospitals, pharmacies, and physicians for more than a century.

Starting late August thru the first week of September, Asthmanefrin will be available nationally in Walmart, closely followed by CVS/pharmacy®, and other retail outlets. The product will be available in a starter kit and a refill package. The starter kit includes 10 Asthmanefrin vials and the EZ Breathe Atomizer. The refill package will include 30 Asthmanefrin vials. The EZ Breathe Atomizer is an OTC device that is intended to spray liquid medication in aerosol form into the air that a person will breathe.

Lou Kennedy, CEO, stated, "Until now, there has been no alternative to fill the void left by Primatene® Mist CFC inhaler. As an industry leader in respiratory medications, introducing Asthmanefrin into the retail market is a natural choice for Nephron. We are proud to bring this quality, low-cost, OTC medication to the market. The use of Asthmanefrin, along with the pocket sized EZ Breathe Atomizer, will give bronchial asthma sufferers an excellent alternative treatment to Primatene® Mist, at an affordable price."

For more information about Asthmanefrin, call 1-855-999-EZAN (3926), or visit www.asthmanefrin.com.

Nephron Pharmaceuticals Corp. is a private, woman owned manufacturer of generic inhalation solutions, headquartered in Orlando, Florida, and employs 500 persons nationwide. Nephron has manufactured billions of doses of life saving medications since 1997. The company is developing a new facility in Cayce, South Carolina, which will expand its product line to include opthalmic and injectable medications, and provide space for contract manufacturing.

Primatene ® Mist is a registered trademark of Armstrong Pharmaceuticals, Inc.

SOURCE Nephron Pharmaceuticals Corporation



Read at BioSpace.com

   

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES
 

//-->